The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
EPIC: A phase III trial of ponatinib (PON) versus imatinib (IM) in patients (pts) with newly diagnosed CP-CML.
Jeffrey Howard Lipton
Consultant or Advisory Role - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer; Teva
Honoraria - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer; Teva
Research Funding - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer; Teva
Charles Chuah
Honoraria - Bristol-Myers Squibb; Novartis
Agnes Guerci-Bresler
No relevant relationships to disclose
Gianantonio Rosti
Consultant or Advisory Role - ARIAD; Bristol-Myers Squibb; Novartis
Honoraria - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer
David Simpson
No relevant relationships to disclose
Stephanie Lustgarten
Employment or Leadership Position - ARIAD
Stock Ownership - ARIAD
Nikolaus S. Trede
Employment or Leadership Position - ARIAD
Stock Ownership - ARIAD
Victor M. Rivera
Employment or Leadership Position - ARIAD
Stock Ownership - ARIAD
Tim Clackson
Employment or Leadership Position - ARIAD
Stock Ownership - ARIAD
Frank G. Haluska
Employment or Leadership Position - ARIAD
Consultant or Advisory Role - ARIAD (I)
Stock Ownership - ARIAD
Honoraria - Lia Gore (I)
Research Funding - ARIAD
Michele Baccarani
Consultant or Advisory Role - ARIAD; Novartis
Honoraria - ARIAD; Novartis
Jorge E. Cortes
Consultant or Advisory Role - ARIAD; Bristol-Myers Squibb; Pfizer; Teva
Research Funding - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer; Teva
Francois Guilhot
Consultant or Advisory Role - ARIAD
Honoraria - ARIAD
Andreas Hochhaus
Honoraria - Bristol-Myers Squibb; Novartis; Pfizer
Research Funding - ARIAD; Bristol-Myers Squibb; M2D; Novartis; Pfizer
Timothy P. Hughes
Consultant or Advisory Role - ARIAD; Bristol-Myers Squibb; Novartis
Honoraria - ARIAD; Bristol-Myers Squibb; Novartis
Research Funding - ARIAD; Bristol-Myers Squibb; Novartis
Hagop M. Kantarjian
Research Funding - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer
Neil P. Shah
Consultant or Advisory Role - ARIAD; Bristol-Myers Squibb
Research Funding - ARIAD; Bristol-Myers Squibb
Moshe Talpaz
Consultant or Advisory Role - ARIAD; Novartis
Honoraria - ARIAD
Research Funding - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer
Michael W.N. Deininger
Consultant or Advisory Role - ARIAD; Bristol-Myers Squibb; Incyte; Novartis
Honoraria - ARIAD; Bristol-Myers Squibb; Incyte; Novartis
Research Funding - Bristol-Myers Squibb; Celgene; Genzyme; Novartis; YM BioSciences